Skip to content
Companies

ImmunoVec

DNA medicines that engineer immune cells inside the body

Raised to date

$12.7M

of $15M offered across 1 Form D filing

Still open
$2.3M
Investors
10
Last filed
Jul 14, 2026

About

ImmunoVec is a Los Angeles biotechnology company developing in vivo cell therapies that use programmable DNA medicines to engineer specific cell types directly inside the patient's body. Its platform combines cell type-specific synthetic promoters with multiple delivery vehicles, including viral vectors and non-viral systems such as DNA-loaded polymeric nanoparticles. The company launched from stealth with an up-to-$40.7 million ARPA-H EMBODY award to advance a first-in-class in vivo cell therapy for autoimmune diseases from pre-clinical studies through a first-in-human trial, and also targets solid tumors and genetic disorders.

Delivery-agnostic precision: proprietary cell type-specific expression cassettes ensure a therapy is expressed only in the intended cells regardless of the delivery vehicle, mitigating off-target risk, and the same cassettes work across viral vectors, lipid nanoparticles, polymeric nanoparticles, and exosomes.

Funding

  • EquityFiled Jul 14, 2026Form D
    $12.7M/ $15M

Product

In vivo cell engineering platform

Cell and gene therapy platform

A platform of programmable DNA medicines that reprogram immune and other cell types directly within the body, led by a pre-clinical in vivo cell therapy program for autoimmune diseases funded by the ARPA-H EMBODY program.

  • Cell type-specific synthetic promoters for precise expression
  • Delivery-agnostic expression cassettes usable across viral and non-viral vehicles
  • DNA-loaded polymeric nanoparticle delivery

Built for

Patients with life-threatening autoimmune diseases, solid tumors, and genetic immune disorders, reached through clinical development and future pharma partnerships

People on file